Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | USP2 | O75604 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | RGS12 | O14924 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16097347 | 0.80 | L3MBTL1 (0.62) | MEN1KMT2AUSP2L3MBTL1KEAP1 | |
| SCHEMBL3284832 | 0.80 | ANPEP (0.50) | MEN1KMT2AUSP2L3MBTL1KEAP1 | |
| SCHEMBL13901466 | 0.78 | KMT2A (0.59) | MEN1KMT2AUSP2KEAP1NFE2L2 | |
| SCHEMBL3285543 | 0.77 | KMT2A (0.62) | MEN1KMT2AUSP2L3MBTL1KEAP1 | |
| SCHEMBL14582061 | 0.77 | DPP4 (0.49) | MEN1KMT2AUSP2L3MBTL1KEAP1 | |
| SCHEMBL23892790 | 0.76 | DPP4 (0.39) | MEN1KMT2AUSP2L3MBTL1KEAP1 | |
| SCHEMBL19720304 | 0.75 | DPP4 (0.54) | MEN1KMT2AUSP2L3MBTL1KEAP1 | |
| SCHEMBL19848822 | 0.75 | DPP4 (0.39) | MEN1KMT2ALMNAS1PR2DPP4 | |
| SCHEMBL6268625 | 0.74 | DPP4 (0.44) | MEN1KMT2AUSP2L3MBTL1KEAP1 | |
| SCHEMBL29544415 | 0.74 | DPP4 (0.44) | MEN1KMT2AUSP2L3MBTL1KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714044-B2 | Use of 4-cyano-naphthalene-1, 8-dicarboximide derivatives and related compounds to protect organic material from the damaging effects of light | BASF AKITENGESELLSCHAFT (DE) | 2010-05-11 | — | — | US | disclosed |
| EP-1687278-B1 | USE OF 4-CYANO-NAPHTHALENE-1, 8-DICARBOXIMIDE DERIVATIVES AND RELATED COMPOUNDS TO PROTECT ORGANIC MATERIAL FROM THE DAMAGING EFFECTS OF LIGHT | BASF SE (DE) | 2009-03-11 | — | — | EP | disclosed |
| US-20070100033-A1 | Use of 4-cyano-naphthalene-1, 8-dicarboximide derivatives and related compounds to protect organic material from the damaging effects of light | BAST AKTIENGESELLSCHAFT (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20050171252-A1 | Use of naphthalin-1,8-dicarboxylic acid monoimides | BASF AKTIENGESELLSCHAFT (DE) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171252-A1 | Use of naphthalin-1,8-dicarboxylic acid monoimides | NDC1, NDUFC1, NDUFC2 | MEN1 512/4885KMT2A 2786/4885USP2 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.